Cargando…
Short-Term Outcomes and Predictors of Effectiveness of Tocilizumab in Systemic Juvenile Idiopathic Arthritis: A Prospective Cohort Study
Background: Systemic Juvenile Idiopathic Arthritis (sJIA) is a unique category of juvenile arthritis in which interleukin 6 plays a major pathogenic role. This study aimed to describe the therapeutic short-term outcomes among patients with sJIA starting tocilizumab (TCZ) therapy and to identify poss...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141590/ https://www.ncbi.nlm.nih.gov/pubmed/34041254 http://dx.doi.org/10.3389/fmed.2021.665028 |
_version_ | 1783696394034348032 |
---|---|
author | Nada, Doaa W. Moghazy, Abdelkawy Allam, Abdallah El-Sayed Alunno, Alessia Ibrahim, Amira M. |
author_facet | Nada, Doaa W. Moghazy, Abdelkawy Allam, Abdallah El-Sayed Alunno, Alessia Ibrahim, Amira M. |
author_sort | Nada, Doaa W. |
collection | PubMed |
description | Background: Systemic Juvenile Idiopathic Arthritis (sJIA) is a unique category of juvenile arthritis in which interleukin 6 plays a major pathogenic role. This study aimed to describe the therapeutic short-term outcomes among patients with sJIA starting tocilizumab (TCZ) therapy and to identify possible predictors of treatment response. Methods: We conducted a prospective observational study including 65 patients with sJIA meeting ILAR classification criteria with active disease despite conventional therapy that were treated by TCZ between August 2019 and October 2020 as the first-line biological therapy. Clinical and serological parameters were recorded at baseline and after 1 year of TCZ therapy. Results: After 1 year, 25% of the patients achieved minimal disease activity and 35% achieved clinically inactive disease. A significant reduction of the 10-joint juvenile arthritis disease activity score and acute phase reactants was also observed. Patients with younger age (≤7 years), shorter disease duration (≤3 years), lower disease activity, and higher serum ferritin and systemic manifestations showed more favorable results. Conclusion: Patients with sJIA showed favorable disease outcomes with TCZ treatment for 1 year, especially if the drugs were administered earlier in the disease course and in younger patients with a more pronounced inflammatory status. Our results may help to define the profile of patients with sJIA who are more likely to benefit from IL-6 blockade. |
format | Online Article Text |
id | pubmed-8141590 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81415902021-05-25 Short-Term Outcomes and Predictors of Effectiveness of Tocilizumab in Systemic Juvenile Idiopathic Arthritis: A Prospective Cohort Study Nada, Doaa W. Moghazy, Abdelkawy Allam, Abdallah El-Sayed Alunno, Alessia Ibrahim, Amira M. Front Med (Lausanne) Medicine Background: Systemic Juvenile Idiopathic Arthritis (sJIA) is a unique category of juvenile arthritis in which interleukin 6 plays a major pathogenic role. This study aimed to describe the therapeutic short-term outcomes among patients with sJIA starting tocilizumab (TCZ) therapy and to identify possible predictors of treatment response. Methods: We conducted a prospective observational study including 65 patients with sJIA meeting ILAR classification criteria with active disease despite conventional therapy that were treated by TCZ between August 2019 and October 2020 as the first-line biological therapy. Clinical and serological parameters were recorded at baseline and after 1 year of TCZ therapy. Results: After 1 year, 25% of the patients achieved minimal disease activity and 35% achieved clinically inactive disease. A significant reduction of the 10-joint juvenile arthritis disease activity score and acute phase reactants was also observed. Patients with younger age (≤7 years), shorter disease duration (≤3 years), lower disease activity, and higher serum ferritin and systemic manifestations showed more favorable results. Conclusion: Patients with sJIA showed favorable disease outcomes with TCZ treatment for 1 year, especially if the drugs were administered earlier in the disease course and in younger patients with a more pronounced inflammatory status. Our results may help to define the profile of patients with sJIA who are more likely to benefit from IL-6 blockade. Frontiers Media S.A. 2021-05-10 /pmc/articles/PMC8141590/ /pubmed/34041254 http://dx.doi.org/10.3389/fmed.2021.665028 Text en Copyright © 2021 Nada, Moghazy, Allam, Alunno and Ibrahim. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Nada, Doaa W. Moghazy, Abdelkawy Allam, Abdallah El-Sayed Alunno, Alessia Ibrahim, Amira M. Short-Term Outcomes and Predictors of Effectiveness of Tocilizumab in Systemic Juvenile Idiopathic Arthritis: A Prospective Cohort Study |
title | Short-Term Outcomes and Predictors of Effectiveness of Tocilizumab in Systemic Juvenile Idiopathic Arthritis: A Prospective Cohort Study |
title_full | Short-Term Outcomes and Predictors of Effectiveness of Tocilizumab in Systemic Juvenile Idiopathic Arthritis: A Prospective Cohort Study |
title_fullStr | Short-Term Outcomes and Predictors of Effectiveness of Tocilizumab in Systemic Juvenile Idiopathic Arthritis: A Prospective Cohort Study |
title_full_unstemmed | Short-Term Outcomes and Predictors of Effectiveness of Tocilizumab in Systemic Juvenile Idiopathic Arthritis: A Prospective Cohort Study |
title_short | Short-Term Outcomes and Predictors of Effectiveness of Tocilizumab in Systemic Juvenile Idiopathic Arthritis: A Prospective Cohort Study |
title_sort | short-term outcomes and predictors of effectiveness of tocilizumab in systemic juvenile idiopathic arthritis: a prospective cohort study |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141590/ https://www.ncbi.nlm.nih.gov/pubmed/34041254 http://dx.doi.org/10.3389/fmed.2021.665028 |
work_keys_str_mv | AT nadadoaaw shorttermoutcomesandpredictorsofeffectivenessoftocilizumabinsystemicjuvenileidiopathicarthritisaprospectivecohortstudy AT moghazyabdelkawy shorttermoutcomesandpredictorsofeffectivenessoftocilizumabinsystemicjuvenileidiopathicarthritisaprospectivecohortstudy AT allamabdallahelsayed shorttermoutcomesandpredictorsofeffectivenessoftocilizumabinsystemicjuvenileidiopathicarthritisaprospectivecohortstudy AT alunnoalessia shorttermoutcomesandpredictorsofeffectivenessoftocilizumabinsystemicjuvenileidiopathicarthritisaprospectivecohortstudy AT ibrahimamiram shorttermoutcomesandpredictorsofeffectivenessoftocilizumabinsystemicjuvenileidiopathicarthritisaprospectivecohortstudy |